These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1091 related items for PubMed ID: 28148281

  • 1. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
    Klingberg E, Strid H, Ståhl A, Deminger A, Carlsten H, Öhman L, Forsblad-d'Elia H.
    Arthritis Res Ther; 2017 Feb 02; 19(1):21. PubMed ID: 28148281
    [Abstract] [Full Text] [Related]

  • 2. A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin.
    Klingberg E, Magnusson MK, Strid H, Deminger A, Ståhl A, Sundin J, Simrén M, Carlsten H, Öhman L, Forsblad-d'Elia H.
    Arthritis Res Ther; 2019 Nov 27; 21(1):248. PubMed ID: 31771630
    [Abstract] [Full Text] [Related]

  • 3. Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum.
    Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H.
    Scand J Gastroenterol; 2012 Apr 27; 47(4):435-44. PubMed ID: 22229862
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.
    J Crohns Colitis; 2015 Jan 27; 9(1):50-5. PubMed ID: 25518048
    [Abstract] [Full Text] [Related]

  • 7. Fecal Calprotectin, Gut Inflammation and Spondyloarthritis.
    Simioni J, Skare TL, Campos APB, Kotze L, Messias-Reason I, Ioshii SO, Nisihara R.
    Arch Med Res; 2019 Jan 27; 50(1):41-46. PubMed ID: 31101242
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V, Day AS, Connor S, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI.
    Gastrointest Endosc; 2017 Dec 27; 86(6):1070-1078. PubMed ID: 28947363
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S.
    Inflamm Bowel Dis; 2015 Feb 27; 21(2):331-6. PubMed ID: 25625487
    [Abstract] [Full Text] [Related]

  • 14. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
    Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.
    Inflamm Bowel Dis; 2014 Feb 27; 20(2):307-14. PubMed ID: 24374878
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M.
    Dig Dis Sci; 2017 Nov 27; 62(11):3123-3130. PubMed ID: 28948412
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Kwapisz L, Gregor J, Chande N, Yan B, Ponich T, Mosli M.
    Scand J Gastroenterol; 2017 Aug 27; 52(8):846-850. PubMed ID: 28423962
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.
    Scand J Gastroenterol; 2016 Aug 27; 51(2):196-202. PubMed ID: 26329773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.